A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

A group of researchers at the VIB‑UGent Center for Medical Biotechnology has developed a new platform to isolate and analyze ...

Aggression is a complex behavior dependent on numerous factors such as personal experiences, upbringing, social context, personality and genetics. Florian Reichmann and his team at the Med Uni Graz ...

Results Identification of a transmembrane CXC chemokine To identify new proteins of immunological interest, we conducted a two-step search of public domain human expressed sequence tag (EST ...

Center for Drug Evaluation (CDE) has granted approval to the investigational new drug (IND) application of InnoCare Pharma to ...

InnoCare receives China NMPA approval to conduct clinical trial of a novel B7-H3 targeted ADC ICP-B794: Beijing Monday, July 7, 2025, 15:00 Hrs [IST] InnoCare Pharma, a leading bi ...

Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...

AbCellera Biologics Inc. (NASDAQ: ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist ...

Using artificial intelligence, researchers show how γ-secretase recognizes substrates – an important advance for fundamental and translational research.

Quantitative measurements of intra-Golgi transport kinetics of diverse secretory cargos challenge the classic cisternal progression model and support the stable compartment model of the Golgi.

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

InnoCare Pharma gets China NMPA approval to conduct clinical trial for a novel ADC ICP-B794 in China: Beijing Saturday, July 5, 2025, 11:00 Hrs [IST] InnoCare Pharma, a commercial ...